cytarabine

(redirected from Depocyt)

cytarabine

 [si-tar´ah-bēn]
an antimetaboliteantineoplastic agent that inhibits DNA polymerase and thus inhibits DNA synthesis during a specific phase of the cell cycle. Administered intravenously to treat acute myelogenous and other types of leukemia. It is also injected intrathecally to treat meningitis associated with leukemia or lymphoma. Called also cytosine arabinoside.

cytarabine

/cy·tar·a·bine/ (ara-C) (si-tar´ah-bēn) an antimetabolite that inhibits DNA synthesis and hence has antineoplastic properties; used in the treatment of acute myelogenous and other types of leukemia and of meningitis associated with leukemia or lymphoma.

cytarabine

(sī-tăr′ə-bēn′)
n.
A cytotoxic compound that inhibits DNA synthesis and is used as a chemotherapeutic agent, usually in combination with other drugs, in the treatment of certain types of leukemia.

cytarabine

[siter′əbēn]
an antineoplastic agent. Also called arabinosylcytosine, ARA-C, cytosine arabinoside.
indications It is prescribed in the treatment of acute and chronic myelocytic leukemia, acute lymphocytic leukemia, and erythroleukemia.
contraindication Known hypersensitivity to this drug prohibits its use.
adverse effects The most serious adverse reactions are bone marrow depression, stomatitis, phlebitis, liver toxicity, fever, and GI disturbances.

cytarabine

AraC, cytosine arabinoside Oncology An antimetabolite analogue of deoxycytidine, used synergistically with antifolates, alkylating agents, and cis-platinum to treat AML Pharmacokinetics Poorly absorbed–±20% absorbed orally, better IV; T1 ⁄ 2, ±2.5 hrs; 90% metabolized to the inactive arabinosyl uracil Side effects N&V, myelosuppression; in high doses, cerebral dysfunction, ataxia

cytarabine

An antimetabolite drug used in the treatment of acute LEUKAEMIA. It is a purine antagonist (see PURINES) and acts by depriving cells of essential metabolic substances. It causes sickness and vomiting, peptic ulcers and depression of bone marrow blood formation. The drug is on the WHO official list. A brand name is Cytosar.

cytarabine

an antimetabolite that inhibits DNA synthesis, and hence has antineoplastic and antiviral properties. Called also cytosine arabinoside, arabinosyl cytosine, ara-C.
References in periodicals archive ?
Its two marketable products are DepoCyt for treating cancer-related neoplastic meningitis and DepoDur for the treatment of post-operative pain.
The speciality pharmaceutical business includes four marketed products, Oncaspar, Adagen, DepoCyt and Abelcet, as well as the manufacturing facility in Indianapolis, Indiana.
Enzon's specialty pharmaceutical division covers the Oncaspar, Adagen, DepoCyt and Abelcet marketed products and a manufacturing facility in Indianapolis, Indiana.
Enzon plans to market Onco TCS through its entire North American sales force of approximately 60 people, which currently markets ABELCET, ONCASPAR, and DEPOCYT to the oncology market.
This growth is primarily attributed to the expected launch of Phase III pipeline candidates Marqibo (vincristine sulfate liposomes injection), GRASPA (asparaginase loaded into erythrocytes), recombinant asparaginase (asparaginase) and Depocyt (liposomal cytarabine) during the forecast period.
The products sold include the cancer drug Oncaspar, fungal infection treatment Abelcet, meningitis drug DepoCyt, and Adagen, which is used for severe combined immunodeficiency disease, or "Bubble Boy Disease.
The specialty pharmaceutical business sold to sigma-tau includes four marketed products, Oncaspar, Adagen, DepoCyt and Abelcet, as well as the manufacturing facility in Indianapolis, Indiana.
Enzon's speciality pharmaceutical business includes the marketed products Oncaspar, Adagen, DepoCyt and Abelcet, as well as a manufacturing facility in Indianapolis, Indiana.
Sales of DepoCyt, a sustained-release formulation of the chemotherapeutic agent cytarabine arabinoside or ara-C, increased to $2.
Received full approval for DepoCyt from FDA in 2007